Global Information
회사소개 | 문의 | 비교리스트

유전자 편집 시장 규모, 점유율 동향 분석 및 부문별 예측(2021-2028년) : 기술(CRISPR, ZFN, TALEN), 전달 방법, 용도, 모드, 최종사용자, 지역별

Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, ZFN, TALEN), By Delivery Method, By Application, By Mode, By End-use, By Region, And Segment Forecasts, 2021 - 2028

리서치사 Grand View Research, Inc.
발행일 2021년 05월 상품코드 1007490
페이지 정보 영문 200 Pages 배송안내 2-10일 (영업일 기준)
가격
US $ 5,950 ₩ 8,452,000 Unprintable PDF (Single User License)
US $ 6,950 ₩ 9,873,000 Printable PDF (5-User License)
US $ 8,950 ₩ 12,714,000 Printable PDF (Enterprise License)


유전자 편집 시장 규모, 점유율 동향 분석 및 부문별 예측(2021-2028년) : 기술(CRISPR, ZFN, TALEN), 전달 방법, 용도, 모드, 최종사용자, 지역별 Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, ZFN, TALEN), By Delivery Method, By Application, By Mode, By End-use, By Region, And Segment Forecasts, 2021 - 2028
발행일 : 2021년 05월 페이지 정보 : 영문 200 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 유전자 편집 시장 규모는 예측 기간 중 22.9%의 CAGR로 추이하며, 2028년에는 194억 달러 규모로 성장할 것으로 예측됩니다.

2020년 CRISPR/Cas9 기술의 성공, TALEN 및 ZFN의 기술적 진보 등의 요인이 이 시장의 성장을 촉진하고 있습니다. 또한 연구자 등은 신종 코로나바이러스 감염증(COVID-19) 게놈의 신속한 스크리닝 솔루션의 가능성으로서 CRISPR과 같은 유전자 개변 툴의 가능성을 모색하고 있습니다.

세계의 유전자 편집 시장을 조사했으며, 시장의 정의와 개요, 신종 코로나바이러스 감염증(COVID-19) 및 기타 시장 영향요인 분석, 법규제 환경, 파이프라인 분석, 시장 규모의 추이·예측, 기술·전달 방법·용도·최종사용자·모드·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 조사 방법

제2장 개요

제3장 산업 전망

  • 시장 피라미드 분석
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
  • 기술의 보급·성장 전망 지도제작
  • SWOT 분석
  • Porter의 산업 분석
  • 파이프라인 분석
  • 지적재산
  • 규제상 문제
  • COVID-19 : 영향 분석

제4장 시장 예측·동향 분석 : 기술별

  • (CRISPR)/Cas9
  • TALEN/MegaTAL
  • ZFN
  • 메가뉴클레아제
  • 기타

제5장 시장 예측·동향 분석 : 전달 방법별

  • 생체외
  • 생체내

제6장 시장 예측·동향 분석 : 용도별

  • 유전자 공학
  • 임상 용도

제7장 시장 예측·동향 분석 : 최종사용자별

  • 바이오테크놀러지·제약기업
  • 학술·정부 연구기관
  • CRO

제8장 시장 예측·동향 분석 : 모드별

  • 자사
  • 계약

제9장 시장 예측·동향 분석 : 지역·주요 국가별

  • 시장 점유율 실적·예측
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동·아프리카

제10장 경쟁 구도

  • 전략적 프레임워크
  • 참여 사업자 분류
  • 전략적 얼라이언스 분석
  • 최근 개발·영향 분석
  • 잠재 사용자 리스트
  • 기업 개요
    • Merck KGaA
    • Cibus
    • Recombinetics, Inc
    • Sangamo
    • Editas Medicine
    • Precision Biosciences
    • CRISPR THERAPEUTICS
    • Intellia Therapeutics, Inc.
    • Caribou Biosciences, Inc
    • Cellectis
    • AstraZeneca
    • Takara Bio Inc.
    • Horizon Discovery Group plc
    • Integrated DNA Technologies, Inc.
    • Transposagen Biopharmaceuticals, Inc.
    • GenScript
    • New England Biolabs
    • OriGene Technologies, Inc.
    • bluebird bio, Inc.
    • Lonza
    • Thermo Fisher Scientific, Inc.
KSA 21.06.03

List of Tables

  • TABLE 1 Genome editing technology comparison
  • TABLE 2 North America genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 3 North America genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 4 North America genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 5 North America genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 6 North America genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 7 North America genome editing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 8 North America genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 9 U.S. genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 10 U.S.genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 11 U.S.genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 12 U.S. genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 13 U.S. genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 14 U.S.genome editing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 15 U.S.genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 16 Canada genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 17 Canada genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 18 Canada genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 19 Canada genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 20 Canada genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 21 Canada genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 22 Canada genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 23 Europe genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 24 Europe genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 25 Europe genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 26 Europe genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 27 Europe genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 28 Europe genome editing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 29 Europe genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 30 Germany genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 31 Germany genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 32 Germany genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 33 Germany genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 34 Germany genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 35 Germany genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 36 Germany genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 37 U.K. genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 38 U.K. genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 39 U.K. genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 40 U.K. genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 41 U.K. genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 42 U.K. genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 43 U.K. genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 44 France genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 45 France genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 46 France genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 47 France genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 48 France genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 49 France genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 50 France genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 51 Italy genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 52 Italy genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 53 Italy genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 54 Italy genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 55 Italy genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 56 Italy genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 57 Italy genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 58 Spain genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 59 Spain genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 60 Spain genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 61 Spain genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 62 Spain genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 63 Spain genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 64 Spain genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 65 Asia Pacific genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 66 Asia Pacific genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 67 Asia Pacific genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 68 Asia Pacific genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 69 Asia Pacific genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 70 Asia Pacific genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 71 Asia Pacific genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 72 Japan genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 73 Japan genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 74 Japan genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 75 Japan genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 76 Japan genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 77 Japan genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 78 Japan genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 79 China genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 80 China genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 81 China genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 82 China genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 83 China genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 84 China genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 85 China genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 86 South Korea genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 87 South Korea genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 88 South Korea genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 89 South Korea genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 90 South Korea genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 91 South Korea genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 92 South Korea genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 93 India genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 94 India genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 95 India genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 96 India genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 97 India genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 99 India genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 100 India genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 101 Latin America genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 102 Latin America genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 103 Latin America genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 104 Latin America genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 105 Latin America genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 106 Latin America genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 107 Latin America genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 108 Brazil genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 109 Brazil genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 110 Brazil genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 111 Brazil genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 112 Brazil genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 113 Brazil genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 114 Brazil genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 115 Mexico genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 116 Mexico genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 117 Mexico genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 118 Mexico genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 119 Mexico genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 120 Mexico genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 121 Mexico genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 122 MEA genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 123 MEA genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 124 MEA genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 125 MEA genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 126 MEA genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 127 MEA genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 128 MEA genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 129 South Africa genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 130 South Africa genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 131 South Africa genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 132 South Africa genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 133 South Africa genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 134 South Africa genome editing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 135 South Africa genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
  • TABLE 136 Saudi Arabia genome editing market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 137 Saudi Arabia genome editing market estimates & forecasts, by delivery method, 2017 - 2028 (USD Million)
  • TABLE 138 Saudi Arabia genome editing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 139 Saudi Arabia genome editing market for genetic engineering estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 140 Saudi Arabia genome editing market for clinical applications estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 141 Saudi Arabia genome editing market estimates & forecasts, by end use,2017 - 2028 (USD Million)
  • TABLE 142 Saudi Arabia genome editing market estimates & forecasts, by mode, 2017 - 2028 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Applications of genome editing in therapeutic models
  • FIG. 12 Market restraint relevance analysis (Current & future impact)
  • FIG. 13 Penetration & growth prospect mapping for technology, 2020
  • FIG. 14 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 15 Porter's Five Forces Analysis
  • FIG. 16 genome editing market: Technology outlook key takeaways
  • FIG. 17 genome editing market: Technology movement analysis
  • FIG. 18 Global (CRISPR)/Cas9market, 2017 - 2028 (USD Million)
  • FIG. 19 Global TALENs/MegaTALs market, 2017 - 2028 (USD Million)
  • FIG. 20 Global ZFN market, 2017 - 2028 (USD Million)
  • FIG. 21 Global meganucleases market, 2017 - 2028 (USD Million)
  • FIG. 22 Global other technologies market, 2017 - 2028 (USD Million)
  • FIG. 23 genome editing market: Delivery method outlook key takeaways
  • FIG. 24 genome editing market: Delivery method movement analysis
  • FIG. 25 Global ex-vivo delivery market, 2017 - 2028 (USD Million)
  • FIG. 26 Global in-vivo delivery market, 2017 - 2028 (USD Million)
  • FIG. 27 genome editing market: Application outlook key takeaways
  • FIG. 28 Global genome editing market: Application movement analysis
  • FIG. 29 Global genetic engineering market, 2017 - 2028 (USD Million)
  • FIG. 30 Global cell line engineering / gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 31 Global animal genetic engineering market, 2017 - 2028 (USD Million)
  • FIG. 32 Global plant genetic engineering market, 2017 - 2028 (USD Million)
  • FIG. 33 Global other applications market, 2017 - 2028 (USD Million)
  • FIG. 34 Global clinical applications market, 2017 - 2028 (USD Million)
  • FIG. 35 Global diagnostic applications market, 2017 - 2028 (USD Million)
  • FIG. 36 Global therapy development applications market, 2017 - 2028 (USD Million)
  • FIG. 37 genome editing market: End-use outlook key takeaways
  • FIG. 38 Global genome editing market: End-use movement analysis
  • FIG. 39 Global biotechnology & pharmaceutical companies market, 2017 - 2028 (USD Million)
  • FIG. 40 Global academic & government research institutes market, 2017 - 2028 (USD Million)
  • FIG. 41 Global CROs market, 2017 - 2028 (USD Million)
  • FIG. 42 genome editing market: Mode outlook key takeaways
  • FIG. 43 Global genome editing market: Mode movement analysis
  • FIG. 44 Global in-house gene editing market, 2017 - 2028 (USD Million)
  • FIG. 45 Global contract gene editing market, 2017 - 2028 (USD Million)
  • FIG. 46 Regional market place: Key takeaway
  • FIG. 47 Genome editing regional outlook, 2020 & 2028
  • FIG. 48 North America genome editing market, 2017 - 2028 (USD Million)
  • FIG. 49 U.S. genome editing market, 2017 - 2028 (USD Million)
  • FIG. 50 Canada genome editing market, 2017 - 2028 (USD Million)
  • FIG. 51 Europe genome editing market, 2017 - 2028 (USD Million)
  • FIG. 52 Germany genome editing market, 2017 - 2028 (USD Million)
  • FIG. 53 U.K. genome editing market, 2017 - 2028 (USD Million)
  • FIG. 54 France genome editing market, 2017 - 2028 (USD Million)
  • FIG. 55 Italy genome editing market, 2017 - 2028 (USD Million)
  • FIG. 56 Spain genome editing market, 2017 - 2028 (USD Million)
  • FIG. 57 Asia Pacific genome editing market, 2017 - 2028 (USD Million)
  • FIG. 58 Japan genome editing market, 2017 - 2028 (USD Million)
  • FIG. 59 China genome editing market, 2017 - 2028 (USD Million)
  • FIG. 60 South Korea genome editing market, 2017 - 2028 (USD Million)
  • FIG. 61 India genome editing market, 2017 - 2028 (USD Million)
  • FIG. 62 Latin America genome editing market, 2017 - 2028 (USD Million)
  • FIG. 63 Brazil genome editing market, 2017 - 2028 (USD Million)
  • FIG. 64 Mexico genome editing market, 2017 - 2028 (USD Million)
  • FIG. 65 Middle East & Africa genome editing market, 2017 - 2028 (USD Million)
  • FIG. 66 South Africa genome editing market, 2017 - 2028 (USD Million)
  • FIG. 67 Saudi Arabia genome editing market, 2017 - 2028 (USD Million)
  • FIG. 68 Strategy framework
  • FIG. 69 Participant categorization

Genome Editing Market Growth & Trends

The global genome editing market size is expected to reach USD 19.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 22.9% from 2021 to 2028. The success of CRISPR/Cas9 technology in 2020 coupled with technological advances in Transcription Activator-Like Effector Nucleases (TALENs) and Zinc-finger Nucleases (ZFNs) with respect to efficiency has driven the market.

Research communities are exploring the potential of gene-modification tools like CRISPR as a potential rapid screening solution for the COVID-19 genome. For instance, in December 2020, researchers from Gladstone Institutes developed a CRISPR-based test that uses smartphones to deliver results. Similarly in June 2020, researchers from Stanford University have developed -PAC-MAN a gene-modification tool based on CRISPR technology. This tool destroys SARS-CoV-2 inside human cells.

Increasing application of the gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor the market revenue in the foreseeable future.

Genome Editing Market Report Highlights

The CRISPR/Cas9 technology segment accounted for the significant revenue share in 2020

The CRISPR/Cas9 technology has proven its efficiency as a promising gene-editing tool owing to its advantages over conventional gene modification methods

One of the significant advantages includes simultaneous modification of multiple target genes using this technology

The ex-vivo delivery method accounted for a major share owing to its ease of DNA modification which resulted in its wide application for genome editing purposes

Genetic engineering, particularly, cell line engineering dominated the market

High penetration of gene-manipulation tools in stem cell research has contributed to this dominance

The application of CRISPR technology has enhanced the productivity of CHO cell lines consequently increasing its application in biopharmaceutical production

Besides, animal genetic engineering is witnessing the growing application of gene-alteration tools for various purposes such as the development of animal models to mirror human diseases

Moreover, the Cas protein system is gaining traction in the development of point-of-care diagnostics, thereby driving investment flow in diagnostic applications

Biotechnology and pharmaceutical companies are the key end-users of the market as these are adopted these technologies for the development of novel therapeutics to a major extent

Also, the COVID-19 pandemic has driven the investments in this space to develop rapid molecular diagnostic tests based on gene editing by biotechnology companies

North America dominated the 2020 global market owing to the strong research as well as the commercial base for various gene alteration tools

Moreover, the U.S. is the major contributor in the region with the high adoption of molecular scissor tools across research

This is indicated by the increasing number of genome editing-based research publications in the country

In Asia Pacific, the market is anticipated to witness the fastest growth rate over the forecast period

China is reported to be the first country to have successfully transferred genetically edited cells into humans, to boost immunity and treat lung cancer, thereby driving the market

Licensing agreements is the major strategy undertaken by operating companies in this space to strengthen their market position

Table of Contents

Chapter 1 Genome Editing Market: Research Methodology

  • 1.1 Information Procurement
  • 1.2 Data Analysis
  • 1.3 Market segmentation & scope
  • 1.4 Market definition
  • 1.5 Information procurement
    • 1.5.1 Purchased database
    • 1.5.2 GVR's internal database
    • 1.5.3 Secondary sources & Third-Party perspectives
    • 1.5.4 Primary research
  • 1.6 Information analysis
    • 1.6.1 Data analysis models
  • 1.7 Market formulation & data visualization
  • 1.8 Data validation & publishing

Chapter 2 Genome Editing Market: Executive Summary

  • 2.1 Genome Editing Market Outlook, 2017 - 2028
  • 2.2 Segment Outlook

Chapter 3 Genome Editing Market: Industry Outlook

  • 3.1 Market Pyramid Analysis
    • 3.1.1 Parent Market
    • 3.1.2 Ancillary Market
  • 3.2 Market Dynamics Analysis
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Success in pre-clinical models drives demands for genome editing therapeutics
      • 3.2.1.2 Rising competition amongst market participants for business development
      • 3.2.1.3 Easy editing solutions for the development of therapeutics for a broad range of diseases
      • 3.2.1.4 Increasing demand for synthetic genes and genetically modified organisms
      • 3.2.1.5 Technological advancements in gene editing technologies
      • 3.2.1.6 Rising adoption in agricultural biotechnology
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Challenges with respect to clinical translation
      • 3.2.2.2 Regulatory, scientific, and ethical challenges pertaining to the use of genetically modified products
      • 3.2.2.3 Off-target effects of CRISPR technology
  • 3.3 Penetration &Growth Prospect MappingforTechnology, 2020
  • 3.4 Genome editing -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.5 Industry Analysis - Porter's
  • 3.6 Genome Editing Technologies: Pipeline Analysis
    • 3.6.1 Sangamo
    • 3.6.2 Cellectis
    • 3.6.3 Calyxt
    • 3.6.4 bluebird bio
    • 3.6.5 Editas Medicine
    • 3.6.6 Intellia Therapeutics, Inc.
    • 3.6.7 CRISPR Therapeutics
    • 3.6.8 Precision Biosciences
    • 3.6.9 Precision Biosciences (Non-medical domain)
    • 3.6.10 Caribou Biosciences
    • 3.6.11 Cibus
    • 3.6.12 Recombinetics, Inc
  • 3.7 Intellectual Property
  • 3.8 Regulatory Issues
    • 3.8.1 Orphan diseases
    • 3.8.2 Germline editing
    • 3.8.3 Safety issues
  • 3.9 COVID-19 Impact Analysis

Chapter 4 Genome Editing Market: Technology Business Analysis

  • 4.1 Genome Editing Market: Technology Movement Analysis
  • 4.2 Genome EditingTechnology Comparison
  • 4.3 (CRISPR)/Cas9
    • 4.3.1 Global (CRISPR)/Cas9 market, 2017 - 2028 (USD Million)
  • 4.4 TALENs/MegaTALs
    • 4.4.1 Global TALENs/MegaTALs market, 2017 - 2028 (USD Million)
  • 4.5 ZFN
    • 4.5.1 Global ZFN market, 2017 - 2028 (USD Million)
  • 4.6 Meganucleases
    • 4.6.1 Global Meganucleases market, 2017 - 2028 (USD Million)
  • 4.7 Other Technologies
    • 4.7.1 Global other technologies market, 2017 - 2028 (USD Million)

Chapter 5 Genome Editing Market: Delivery Method Business Analysis

  • 5.1 Genome Editing Market: Delivery Method Movement Analysis
    • 5.1.1 Comparison of Delivery Methods
      • 5.1.1.1 Viral delivery
      • 5.1.1.1.1 AAV (Adeno Associated Virus)
      • 5.1.1.1.2 IDLV (Integrase Deficient Lentivirus).
      • 5.1.1.2 Non-viral delivery
      • 5.1.1.2.1 Lipid Mediated
      • 5.1.1.2.2 Electroporation
  • 5.2 Ex-vivo
    • 5.2.1 Global ex-vivo delivery market, 2017 - 2028 (USD Million)
  • 5.3 In-vivo
    • 5.3.1 Global in-vivo delivery market, 2017 - 2028 (USD Million)

Chapter 6 Genome Editing Market: Application Business Analysis

  • 6.1 Market: ApplicationMovement Analysis
  • 6.2 Genetic Engineering
    • 6.2.1 Market, 2017 - 2028 (USD Million)
      • 6.2.1.1 Cell line engineering
      • 6.2.1.1.1 Market, 2017 - 2028 (USD Million)
      • 6.2.1.2 Animal genetic engineering
      • 6.2.1.2.1 Market, 2017 - 2028 (USD Million)
      • 6.2.1.3 Plant genetic engineering
      • 6.2.1.3.1 Market, 2017 - 2028 (USD Million)
      • 6.2.1.4 Others
      • 6.2.1.4.1 Global others market, 2017 - 2028 (USD Million)
  • 6.3 Clinical Applications
    • 6.3.1 Market for clinical applications, 2017 - 2028 (USD Million)
      • 6.3.1.1 Diagnostics
      • 6.3.1.1.1 Market for diagnostics applications, 2017 - 2028 (USD Million)
      • 6.3.1.2 Therapy Development
      • 6.3.1.2.1 Market for therapy development applications, 2017 - 2028 (USD Million)

Chapter 7 Genome Editing Market: End-Use Business Analysis

  • 7.1 Market: End-use Movement Analysis
  • 7.2 Biotechnology & Pharmaceutical Companies
    • 7.2.1 Market, 2017 - 2028 (USD Million)
  • 7.3 Academic & Government Research Institutes
    • 7.3.1 Market, 2017 - 2028 (USD Million)
  • 7.4 Contract Research Organizations (CROs)
    • 7.4.1 Market, 2017 - 2028 (USD Million)

Chapter 8 Genome Editing Market: Mode Business Analysis

  • 8.1 Market: Mode Movement Analysis
  • 8.2 In-house
    • 8.2.1 Market, 2017 - 2028 (USD Million)
  • 8.3 Contract
    • 8.3.1 Market, 2017 - 2028 (USD Million)

Chapter 9 Genome Editing Market: Regional Business Analysis

  • 9.1 Market Share By Region, 2020 & 2028
  • 9.2 North America
    • 9.2.1 Market, 2017 - 2028 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.2.2.2 U.S. genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.2.2.3 U.S. genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.2.2.4 U.S. genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.2.2.5 U.S. genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.2.3.2 Canada genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.2.3.3 Canada genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.2.3.4 Canada genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.2.3.5 Canada genome editing market, by mode, 2017 - 2028 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe genome editing market, 2017 - 2028 (USD Million)
    • 9.3.2 Germany
      • 9.3.2.1 Germany genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.3.3.2 Germany genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.3.3.3 Germany genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.3.3.4 Germany genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.3.3.5 Germany genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.3.3 U.K.
      • 9.3.3.1 U.K. genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.3.3.2 U.K. genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.3.3.3 U.K. genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.3.3.4 U.K. genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.3.3.5 U.K. genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.3.4 Italy
      • 9.3.4.1 Italy genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.3.4.2 Italy genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.3.4.3 Italy genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.3.4.4 Italy genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.3.4.5 Italy genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.3.5 France
      • 9.3.5.1 France genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.3.5.2 France genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.3.5.3 France genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.3.5.4 France genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.3.5.5 France genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.3.6 Spain
      • 9.3.6.1 Spain genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.3.6.2 Spain genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.3.6.3 Spain genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.3.6.4 Spain genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.3.6.5 Spain genome editing market, by mode, 2017 - 2028 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific genome editing market, 2017 - 2028 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.4.2.2 Japan genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.4.2.3 Japan genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.4.2.4 Japan genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.4.2.5 Japan genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.4.3.2 China genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.4.3.3 China genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.4.3.4 China genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.4.3.5 China genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.4.4 South Korea
      • 9.4.4.1 South Korea genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.4.4.2 South Korea genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.4.4.3 South Korea genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.4.4.4 South Korea genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.4.4.5 South Korea genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.4.5 India
      • 9.4.5.1 India genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.4.5.2 India genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.4.5.3 India genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.4.5.4 India genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.4.5.5 India genome editing market, by mode, 2017 - 2028 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America genome editing market, 2017 - 2028 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.5.2.2 Brazil genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.5.2.3 Brazil genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.5.2.4 Brazil genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.5.2.5 Brazil genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.5.3 Mexico
      • 9.5.3.1 Mexico genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.5.3.2 Mexico genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.5.3.3 Mexico genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.5.3.4 Mexico genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.5.3.5 Mexico genome editing market, by mode, 2017 - 2028 (USD Million)
  • 9.6 Middle East & Africa
    • 9.6.1 Middle East & Africa genome editing market, 2017 - 2028 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.6.2.2 South Africa genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.6.2.3 South Africa genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.6.2.4 South Africa genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.6.2.5 South Africa genome editing market, by mode, 2017 - 2028 (USD Million)
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Saudi Arabia genome editing market, by technology, 2017 - 2028 (USD Million)
      • 9.6.3.2 Saudi Arabia genome editing market, by delivery method, 2017 - 2028 (USD Million)
      • 9.6.3.3 Saudi Arabia genome editing market, by application, 2017 - 2028 (USD Million)
      • 9.6.3.4 Saudi Arabia genome editing market, by end-use, 2017 - 2028 (USD Million)
      • 9.6.3.5 Saudi Arabia genome editing market, by mode, 2017 - 2028 (USD Million)

Chapter 10 Genome Editing Market: Competitive Landscape

  • 10.1 Strategy Framework
  • 10.2 Market Participation Categorization
  • 10.3 Strategic Alliance Analysis
    • 10.3.1 Mergers & Acquisitions
    • 10.3.2 Technological Collaborations
    • 10.3.3 Licensing and partnership
  • 10.4 Recent Developments & Impact Analysis
  • 10.5 List of Potential End-users
  • 10.6 Company Profiles
    • 10.6.1 Merck KGaA
      • 10.6.1.1 Company overview
      • 10.6.1.1.1 Sigma-Aldrich Co. LLC
      • 10.6.1.2 Financial performance
      • 10.6.1.3 Product benchmarking
      • 10.6.1.4 Strategic initiatives
    • 10.6.2 Cibus
      • 10.6.2.1 Company overview
      • 10.6.2.1.1 Nucelis
      • 10.6.2.2 Financial performance
      • 10.6.2.3 Product benchmarking
      • 10.6.2.4 Strategic initiatives
    • 10.6.3 Recombinetics, Inc
      • 10.6.3.1 Company overview
      • 10.6.3.2 Financial performance
      • 10.6.3.3 Product benchmarking
      • 10.6.3.4 Strategic initiatives
    • 10.6.4 Sangamo
      • 10.6.4.1 Company overview
      • 10.6.4.2 Financial performance
      • 10.6.4.3 Product benchmarking
      • 10.6.4.4 Strategic initiatives
    • 10.6.5 Editas Medicine
      • 10.6.5.1 Company overview
      • 10.6.5.2 Financial performance
      • 10.6.5.3 Product benchmarking
      • 10.6.5.4 Strategic initiatives
    • 10.6.6 Precision Biosciences
      • 10.6.6.1 Company overview
      • 10.6.6.2 Financial performance
      • 10.6.6.3 Product benchmarking
      • 10.6.6.4 Strategic initiatives
    • 10.6.7 CRISPR THERAPEUTICS
      • 10.6.7.1 Company overview
      • 10.6.7.2 Financial performance
      • 10.6.7.3 Product benchmarking
      • 10.6.7.4 Strategic initiatives
    • 10.6.8 Intellia Therapeutics, Inc.
      • 10.6.8.1 Company overview
      • 10.6.8.2 Financial performance
      • 10.6.8.3 Product benchmarking
      • 10.6.8.4 Strategic initiatives
    • 10.6.9 Caribou Biosciences, Inc
      • 10.6.9.1 Company overview
      • 10.6.9.2 Financial performance
      • 10.6.9.3 Product benchmarking
      • 10.6.9.4 Strategic initiatives
    • 10.6.10 Cellectis
      • 10.6.10.1 Company overview
      • 10.6.10.2 Financial performance
      • 10.6.10.3 Product benchmarking
      • 10.6.10.4 Strategic initiatives
    • 10.6.11 AstraZeneca
      • 10.6.11.1 Company overview
      • 10.6.11.2 Financial performance
      • 10.6.11.3 Product benchmarking
      • 10.6.11.4 Strategic initiatives
    • 10.6.12 Takara Bio Inc.
      • 10.6.12.1 Company overview
      • 10.6.12.2 Financial performance
      • 10.6.12.3 Product benchmarking
      • 10.6.12.4 Strategic initiatives
    • 10.6.13 Horizon Discovery Group plc
      • 10.6.13.1 Company overview
      • 10.6.13.2 Financial performance
      • 10.6.13.3 Product benchmarking
      • 10.6.13.4 Strategic initiatives
    • 10.6.14 Integrated DNA Technologies, Inc.
      • 10.6.14.1 Company overview
      • 10.6.14.2 Financial performance
      • 10.6.14.3 Product benchmarking
    • 10.6.15 Transposagen Biopharmaceuticals, Inc.
      • 10.6.15.1 Company overview
      • 10.6.15.2 Financial performance
      • 10.6.15.3 Product benchmarking
    • 10.6.16 GenScript
      • 10.6.16.1 Company overview
      • 10.6.16.2 Financial performance
      • 10.6.16.3 Product benchmarking
      • 10.6.16.4 Strategic initiatives
    • 10.6.17 New England Biolabs
      • 10.6.17.1 Company overview
      • 10.6.17.2 Financial performance
      • 10.6.17.3 Product benchmarking
      • 10.6.17.4 Strategic initiatives
    • 10.6.18 OriGene Technologies, Inc.
      • 10.6.18.1 Company overview
      • 10.6.18.2 Financial performance
      • 10.6.18.3 Product benchmarking
      • 10.6.18.4 Strategic initiatives
    • 10.6.19 bluebird bio, Inc.
      • 10.6.19.1 Company overview
      • 10.6.19.2 Financial performance
      • 10.6.19.3 Product benchmarking
      • 10.6.19.4 Strategic initiatives
    • 10.6.20 Lonza
      • 10.6.20.1 Company overview
      • 10.6.20.2 Financial performance
      • 10.6.20.3 Product benchmarking
      • 10.6.20.4 Strategic initiatives
    • 10.6.21 Thermo Fisher Scientific, Inc.
      • 10.6.21.1 Company overview
      • 10.6.21.2 Financial performance
      • 10.6.21.3 Product benchmarking
      • 10.6.21.4 Strategic initiatives
Back to Top
전화 문의
F A Q